Comparative Pharmacology
Head-to-head clinical analysis: ADMELOG versus HUMALOG KWIKPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADMELOG versus HUMALOG KWIKPEN.
ADMELOG vs HUMALOG KWIKPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin lispro is a rapid-acting insulin analog that binds to the insulin receptor, activating downstream signaling pathways to facilitate cellular glucose uptake, inhibit hepatic gluconeogenesis, and promote glycogen synthesis, lipogenesis, and protein synthesis.
Insulin lispro is a rapid-acting insulin analog that lowers blood glucose by binding to insulin receptors on skeletal muscle and adipose tissue, facilitating glucose uptake, and inhibiting hepatic glucose production.
Subcutaneous injection: 0.2-1.0 units/kg/day divided into 2-4 doses. Typical starting dose: 0.4-0.6 units/kg/day. Administer within 15 minutes before or immediately after a meal.
Subcutaneous injection: individualize dose; typical total daily dose 0.5-1 unit/kg; rapid-acting insulin given 0-15 minutes before or immediately after meals.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-2.5 hours (subcutaneous administration). This short half-life reflects rapid absorption and clearance, suitable for prandial glucose control.
Terminal elimination half-life: approximately 26 minutes (range 0.6-1.2 hours in some studies) following subcutaneous administration, reflecting rapid clearance from the systemic circulation.
Renal (primarily as unchanged drug, following degradation by insulin-degrading enzyme). Approximately 60-80% of a dose is excreted renally; the remainder is metabolized in the liver and kidneys.
Renal: 60-80% of insulin lispro is metabolized primarily in the liver and kidneys, with metabolites and a small amount of intact drug excreted in urine.
Category C
Category C
Insulin
Insulin